|
|||||||
| Register | FAQ | Members List | Calendar | Search | Today's Posts | Mark Forums Read |
| Plastic Surgery News Latest Plastic Surgery News |
![]() |
|
|
LinkBack | Thread Tools | Display Modes |
|
|||
|
Mentor Corporation (NYSE:MNT), a leading supplier of medical products for the global aesthetic market, announced that subject enrollment and initial dosing in its pivotal Phase IIIb study of its investigational botulinum toxin type A for the reduction of glabellar rhytides (frown lines) by intramuscular injection has been completed.
More... |